Testing new drug combinations for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can understand and sign consent.
- Your cancer is breast cancer that has spread to other parts of the body (metastatic) or cannot be fully removed by surgery (locally advanced).
- At least one visible tumor spot can be measured (a “target lesion”), and doctors can find enough tumor tissue for biopsy testing.
- Your overall health is good enough for study treatment (ECOG 0–1) and you’re expected to live at least 3 months.
- Your blood and organ tests (kidney, liver, etc.) are adequate based on recent lab results within 14 days.
- You can follow study visits and treatment rules, including pregnancy prevention rules if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
This trial tests different combinations of the drug Inetetamab as a first treatment for breast cancer that has spread and is HER2-positive. It aims to find which combo works best and is safe for newly diagnosed metastatic patients.
This early-phase trial tests several combinations of cancer medicines to slow or control ER-positive breast cancer that has returned or progressed. It also checks safety and whether tumor or blood biomarkers can help match the right treatment to the right person.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.